

For babies with RDS,
Tomorrow is made possible by:

Infasurf[®] (calfactant)



- ◉ Ready to use. No mixing or warming or reconstitution is required¹
- ◉ Only surfactant that retains surfactant cholesterol²
- ◉ Lung lavage vs minced manufacturing process³
- ◉ Lowest dynamic and surface viscosity^{4,5}
- ◉ Proven safe and Biophysically potent^{4,6,7}
- ◉ Sustained respiratory improvement^{6,8}
- ◉ Highest SP-B to phospholipid ratio¹
- ◉ Rapid onset of action⁸
- ◉ Single dose success^{9,10,11}
- ◉ No preservatives¹
- ◉ Cost effective¹⁰

RX Code:

Vial 3 ml: 60499



RX Code:

Vial 6 ml: 60500



Made in USA

Infasurf[®] Mirrors native lung surfactant

Native Lung Surfactant³



• 41% Disaturated Phosphatidylcholine (DSPC)

• 10% Phosphatidyl Glycerol (PG)

• 5% Cholesterol (Chol)

• 4% Other Phospholipids (PLS)

• 9% SP-A

• 2% SP-B, SP-C

• 29% Unsaturated Phosphatidylcholine (USPC)

Infasurf[®] (calfactant)^{1,2,12}

(35 mg Phospholipid and 0.7 mg protein / 1 ml)

Infasurf[®] is native lung surfactant without SP-A

**Same % of SP-B
To Total Phospholipids**

0/74%

**Retains Natural
Cholesterol Level**

5%

Infasurf[®] FDA-labeled Indication¹

- Prevention of Respiratory Distress Syndrome in premature infants at high risk for RDS.
- Treatment of premature infants who develop RDS.

Infasurf decreases the incidence of RDS, mortality due to RDS, and air leaks associated with RDS.

References:

1. Infasurf[®] (calfactant) Intratracheal suspension prescribing information, ONY Biotech, March, 2018 and FDA label.
2. Kim K, Choi S, Zell Z, et al. Effect of cholesterol nanodomains on monolayer morphology and dynamics. Proc Natl Acad Sci USA. 2013;110:E3054-60.
3. Notter RH. Lung Surfactants. Michael Dekker, New York, 2000, pp 171-232; 319-345.
4. Wang Z, Notter RH. Additivity of protein and nonprotein inhibitors of lung surfactant activity. Am J Respir Crit Care Med. 1998;158:28-35.
5. Swartz D, Klein W, Row S, et al. Comparison of dynamic viscosities of lung surfactant drugs. Poster presented Hot Topics. 2017.
6. Attar M, Becker M, Dechert R, et al. Immediate changes in lung compliance following natural surfactant administration in premature infants with Respiratory Distress Syndrome: a controlled trial. J Perinatol. 2004;24:626-630.
7. Seeger W, Gruba C, Gunther A, et al. Surfactant inhibition by plasma proteins: differential sensitivity of various surfactant preparations. Eur Respir J. 1993;6:971-977.
8. Bloom BT, Kattwinkel J, Hall RT, et al. Comparison of Infasurf (calf lung surfactant extract) to Surfactant (beractant) in the treatment and prevention of Respiratory Distress Syndrome. Pediatrics. 1997;100:31-38.
9. Jeon GW, Oh M, Sin JB. Efficacy of surfactant-TA, calfactant and poractant alfa for preterm infants with Respiratory Distress Syndrome: A retrospective study. Yonsei Med J. 2015;56(2):433-439.
10. Zayek MM, Eyal FG, Smith RC. Comparison of the pharmacoeconomics of calfactant and poractant alfa in surfactant replacement therapy. JPPT. 2018;23(2):146-151.
11. Gerdes JS, Seiberlich W, Siveri EM, et al. An open label comparison of calfactant and poractant alfa administration traits and impact on neonatal intensive care unit resources. J Pediatr Pharmacol Ther. 2006;11(2):92-100.
12. Mizuno K, Ikagami M, Chen C-M, et al. Surfactant protein-B supplementation improves in vivo function of a modified natural surfactant. Pediatr Res. 1995;37: 271-276.

